Yanrong Luo
Overview
Explore the profile of Yanrong Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu J, Luo Y, Wang L, Wang T, Ye M, Chen J, et al.
Cancer Med
. 2024 May;
13(10):e7310.
PMID: 38785213
Background: To explore the effects of monitoring measurable residual disease and post-remission treatment selection on the clinical outcomes of B-cell acute lymphoblastic leukemia (B-ALL) in adults. Methods: Between September 2010...
2.
Fan Y, Yang T, Liu Y, Gan H, Li X, Luo Y, et al.
Perioper Med (Lond)
. 2024 May;
13(1):34.
PMID: 38702728
Objective: To retrospectively analyze the risk factors for postoperative delirium (POD) after orthopedic surgery in elderly patients and establish an individualized nomogram to predict the risk of POD. Methods: The...
3.
Fu W, Gao S, Luo Y, Chen L, Chen J, Gao L, et al.
Transplant Cell Ther
. 2023 Nov;
30(2):245.e1-245.e8.
PMID: 37977336
The preferred donor (haploidentical donor [HID] versus matched unrelated donor [URD]) choice in patients with acquired severe aplastic anemia (SAA) who lack an HLA-matched sibling donor (MSD) and fail upfront...
4.
Wang T, Liu P, Xu L, Gao L, Ni X, Tang G, et al.
Ann Hematol
. 2023 Nov;
103(2):575-582.
PMID: 37932468
Autologous stem cell transplantation (ASCT) is a salvage therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). We have developed a novel conditioning regimen called CEAC (oral semustine 250 ...
5.
Fu W, Huang A, Luo Y, Liu M, Tang G, Yang J, et al.
Mol Clin Oncol
. 2023 Aug;
19(3):75.
PMID: 37614372
Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma cell disorder, which accounts for ~70% of all PCL. Survival of pPCL remains poor, and is related...
6.
Wang S, Xiong L, Ruan Z, Gong X, Luo Y, Wu C, et al.
Mol Med
. 2023 May;
29(1):65.
PMID: 37208586
Background: The morbidity and mortality of sepsis are extremely high, which is a major problem plaguing human health. However, current drugs and measures for the prevention and treatment of sepsis...
7.
Huang P, Cao J, Chen J, Luo Y, Gong X, Wu C, et al.
Front Cell Infect Microbiol
. 2022 Sep;
12:1015825.
PMID: 36132990
Renal ischemia-reperfusion injury (IRI) is the main cause of acute kidney injury and the cause of rapid renal dysfunction and high mortality. In recent years, with the gradual deepening of...
8.
Zhao D, Fang X, Fan W, Meng L, Luo Y, Chen N, et al.
Front Oncol
. 2022 Sep;
12:960490.
PMID: 36119537
Purpose: To identify and compare the value of functional MRI (fMRI) in predicting the early response of metastatic cervical lymph nodes (LNs) to induction chemotherapy (IC) in nasopharyngeal carcinoma (NPC)...
9.
Chen J, Wang Y, Shi Y, Liu Y, Wu C, Luo Y
Front Cell Infect Microbiol
. 2022 Jul;
12:962782.
PMID: 35903197
Intestinal ischemia/reperfusion (II/R) is a common acute and critical condition in clinical practice with a high mortality rate. However, there is still a lack of effective prevention and treatment measures...
10.
Luo Y, Cai B, Li B, Liu F, Du L, Zhao D, et al.
Technol Cancer Res Treat
. 2022 Jun;
21:15330338221109974.
PMID: 35770295
The objective of this trial is to evaluate and compare the acute toxicity in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) treated with docetaxel plus cisplatin, or docetaxel, or cisplatin...